43.71 0.00 (0.00%)
After hours: 7:10PM EST
|Bid||43.69 x 900|
|Ask||43.70 x 3100|
|Day's Range||43.66 - 44.17|
|52 Week Range||31.56 - 44.22|
|Beta (3Y Monthly)||0.78|
|PE Ratio (TTM)||56.77|
|Earnings Date||Feb 4, 2020 - Feb 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.36|
This week's military contracting roundup features three contract notices for food distribution, staffing of certified registered nurse anesthetists and neurostimulator implantable devices, as well as solicitations for four contracts at Joint Base San Antonio.
Does the December share price for Boston Scientific Corporation (NYSE:BSX) reflect what it's really worth? Today, we...
The drug makers and medical device firms that made the most payments to District physicians and health systems last year include a handful of industry giants with deep local ties.
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and deteriorating expectations towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the third quarter and hedging or reducing many of […]
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MARLBOROUGH, Mass. , Nov. 21, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two investor conferences this December. On Wednesday, December 4, 2019 , Susie ...
One of the most attractive reasons to invest in health-care stocks continues to be the world's aging population.The United Nations says people age 65 and older are the fastest-growing age group worldwide. It estimates that by 2050, one out of every six people will be 65 or older, accounting for 16% of the planet's total population, up from 9% in 2011. That figure is even larger in Europe and North America, where the U.N. predicts the number will be closer to 25%. The demand for health-care products and services should only increase as a result.Yes, health-care stocks will be coming off a weak 2019. Through mid-November, the S&P; 500 was sitting on nearly 25% gains, while the sector had improved by roughly half that. They'll also have to contend with uncertainty regarding the future of health care as the 2020 presidential election approaches. But don't sleep on the space in the year ahead.For one, health-care stocks tend to outperform during periods of economic weakness. For instance, the Health Care Select Sector SPDR Fund (XLV) delivered a 39.6% total loss (share price plus dividends) during the 2007-09 bear market - more than 15 percentage points better than the S&P; 500\. Thus, headlines warning of an economic slowdown or even a recession in 2020 actually bode well for the sector.Also, health care has traded at a price-to-earnings ratio more expensive than the overall market more often than not over the past 20 years. However, according to the Charles Schwab Center for Research, the sector's P/E currently is cheaper than the S&P; 500, providing a better buying opportunity.Here, then, are the 13 best health-care stocks to buy for 2020, including a couple of funds for investors who want to diversify. SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio
Many patients with severe but stable heart disease who routinely undergo invasive procedures to clear and prop open clogged arteries would do as well by just taking medications and making lifestyle changes, U.S. researchers reported on Saturday. The $100 million government-backed study, presented at the American Heart Association (AHA) meeting in Philadelphia, is the largest yet to look at whether procedures to restore normal blood flow in patients with stable heart disease offers an added benefit over more conservative treatment with aspirin, cholesterol-lowering drugs and other measures. At least two prior studies determined that artery-clearing and stenting or bypass surgery in addition to medical treatment does not significantly lower the risk of heart attacks or death compared with non-invasive medical approaches alone.
Boston Scientific Corporation (NYSE: BSX) are up 8.5% since the company reported third-quarter earnings in late October. At 10:10 a.m., a trader sold 1,656 Boston Scientific call options with a $33 strike price expiring on Jan. 17, 2020 at the bid price of 64.1 cents. At 10:12 a.m., a trader bought 620 Boston Scientific call options with a $42.50 strike price expiring on Nov. 29 near the ask price at 40.9 cents.
MARLBOROUGH, Mass. , Nov. 12, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) (the "Company") completed a public offering of €900.0 million aggregate principal amount of 0.625% ...
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Firms have a variety of reasons for forgoing dividends. But some say Berkshire Hathaway, Facebook, and others have the means and should initiate dividends.
MARLBOROUGH, Mass., Nov. 6, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's shelf registration statement. The Company expects to receive the net offering proceeds upon closing on November 12, 2019, subject to customary closing conditions. The Company intends to use the net proceeds from the offering to (i) fund the previously announced tender offer for up to $1.0 billion in aggregate principal amount of certain series of the Company's senior notes (the "Tender Offer") and (ii) pay accrued and unpaid interest, premiums, fees and expenses in connection with the Tender Offer.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured notes offering of Boston Scientific Corporation ("Boston Scientific"). There are no changes to Moody's existing ratings of Boston Scientific including the Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. Moody's views the transaction as a credit positive as it will lower Boston Scientific's interest expense.
MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) today announced the pricing terms of the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes listed in the table below (the "Securities"). The table below summarizes certain information regarding the Securities and the Tender Offer, including the order of priority and purchase price information for the Securities.
LAS VEGAS and MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ -- Today, Boston Scientific (BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at Vascular InterVentional Advances (VIVA) meeting in Las Vegas. The RANGER II SFA study evaluated the safety and effectiveness of the Ranger DCB, which has a low drug dose density of paclitaxel, versus standard percutaneous transluminal angioplasty (PTA) for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
Third-quarter EPS season is in the homestretch, with blue-chip Utilities, Financial Services, Consumer and Industrial companies all releasing reports. Through 11/1/2019, Refinitiv reported that 356 S&P 500 companies have now announced 3Q earnings, with 76% coming in above consensus, ahead of the past four-quarters average percentage of 74%. The better-than-expected results have improved the overall forecast for the quarter to a -0.8%, from -3.2% at the start of the reporting season. Our analysts are always on the lookout for companies that raise their outlooks during earnings season. Management’s ability to “raise guidance” can often be a catalyst to strong returns in the quarters ahead. Following are 12 BUY-rated companies in Argus coverage for which management has raised guidance during the current EPS reporting season.
MARLBOROUGH, Mass., Nov. 5, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes listed in the table below (the "Securities"), approximately $1.6 billion in aggregate principal amount of the Securities were validly tendered and not validly withdrawn on or prior to 5:00 p.m., Eastern Standard Time (EST), on November 4, 2019 (the "Early Tender Date"). Withdrawal rights for the Tender Offer expired at 5:00 p.m. EST on November 4, 2019, and, accordingly, Securities validly tendered in the Tender Offer may no longer be withdrawn except where additional withdrawal rights are required by law.
MARLBOROUGH, Mass. , Nov. 1, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in four conferences, including one industry conference and three investor conferences, this ...